Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib

BACKGROUND: Imatinib mesylate is an inhibitor of the tyrosine kinase Bcr–Abl and a first-line treatment for Philadelphia chromosome-positive chronic myeloid leukaemia (CML). Dermatological side effects include superficial oedema, pustular eruption, lichenoid reactions, erythroderma, and skin rash. D...

Descripción completa

Detalles Bibliográficos
Autores principales: Bombeccari, Gian Paolo, Garagiola, Umberto, Pallotti, Francesco, Rossi, Margherita, Porrini, Massimo, Giannì, Aldo Bruno, Spadari, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714941/
https://www.ncbi.nlm.nih.gov/pubmed/29230387
http://dx.doi.org/10.1186/s40902-017-0136-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714941/
https://www.ncbi.nlm.nih.gov/pubmed/29230387
http://dx.doi.org/10.1186/s40902-017-0136-y

Ejemplares similares